Safety and Efficacy Study to Compare Capecitabine + Bevacizumab Versus Capecitabine, Concomitantly With Radiotherapy as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer
The purpose of the study is to evaluate the efficacy and safety of the combination of capecitabine + bevacizumab concomitantly with radiotherapy versus capecitabine concomitantly with radiotherapy, as neoadjuvant treatment for patients with localized and resectable rectal cancer.
Rectal Cancer
DRUG: Bevacizumab + Capecitabine + Radiotherapy|DRUG: Capecitabine + Radiotherapy
Rate complete pathologic responses, 17 months
Disease free survival at 3 and 5 years, 78 months|Rate of local and distant recurrence at 3 and 5 years, 78 months|Overall survival at 3 and 5 years, 78 months|R0 resection rate., 17 months|Adverse events, 17 months|Rate of surgery complications, 17 months|Molecular predictive markers: changes in angiogenic parameters, vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptors, microvessel quantification and angiopoietin-2 (Ang-2), 17 months|Rate of sphincter preservation, 17 months
The purpose of the study is to evaluate the efficacy and safety of the combination of capecitabine + bevacizumab concomitantly with radiotherapy versus capecitabine concomitantly with radiotherapy, as neoadjuvant treatment for patients with localized and resectable rectal cancer.